Novo Nordisk Faces Legal and Investor Challenges Over Semaglutide Sales and Safety Concerns
Novo Nordisk has filed over 130 lawsuits across 40 states to combat illegal marketing and sale of unsafe, non-FDA-approved compounded semaglutide products, which pose serious health risks due to illicit ingredients and misleading claims. The company is actively working to protect patients through legal action, education campaigns, and advocating for stricter enforcement against counterfeit and unapproved drugs.